Research news from ADA 2019

Delaying diabetes onset by at least 6 years in people with impaired glucose tolerance significantly reduces their risk for cardiovascular disease and microvascular complications, show 30-year data from the Da Qing Diabetes Prevention Study.

Patients with type 2 diabetes last for longer before needing treatment intensification if they are treated with fixed-ratio combination insulin degludec and liraglutide rather than insulin glargine 100 U/mL, show the DUAL VIII findings.

Although a rare occurrence, non-maintenance of two or more type 1 diabetes autoantibodies may be associated with a reduced risk for progression to diabetes, show data presented at the 79th ADA Scientific Sessions in San Francisco, California, USA.

The latest analysis from the observational follow-up of the TODAY study participants shows rapid accumulation of cardiovascular risk factors and diabetes complications in people who were diagnosed with type 2 diabetes in youth.

Data from the phase IIIa PIONEER 2 and PIONEER 4 studies show that semaglutide equals or betters both empagliflozin and liraglutide for the reduction of glycated hemoglobin in patients with type 2 diabetes uncontrolled on metformin.

High-dose vitamin D supplementation does not significantly reduce the risk for developing type 2 diabetes among people with prediabetes, show D2d trial data.

People with type 2 diabetes have a high prevalence of pathogenic mutations in genes typically associated with monogenic diabetes.